To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

August 03, 2018

Today's Rundown

Featured Story

Fortress Bio’s in-house stockbrokers raised $240M to support its young biotechs: Reuters

Fortress Biotech used its own in-house brokerage firm, National Securities, to raise at least $240 million from thousands of individual investors to support itself and its biotech subsidiaries—employing analysts bullish on its own companies’ prospects without fully disclosing their connections to their parent, according to a monthslong investigation by Reuters.

Top Stories

CAR-T player Cellectis poaches Stefan Scherer from Novartis

Cellectis has named Stefan Scherer, M.D., Ph.D., as its SVP of clinical development. Scherer joins the off-the-shelf CAR-T pioneer from Novartis, where he headed up U.S. oncology early development and strategy.

Thomas Hughes leaves Zafgen to take CEO role at Navitor

Thomas Hughes, Ph.D., has left Zafgen to become CEO at mTORC1 startup Navitor Pharmaceuticals. Hughes helmed Zafgen through a turbulent time in which it abandoned its lead candidate after patients died in a phase 3 study.

A better enzyme for CRISPR gene editing?

The gene editing system CRISPR-Cas9 is promising for its potential to treat diseases caused by gene irregularities, but fears of off-target effects threaten to delay its development. New research suggests that using a different protein, Cas12a, may be the best way to address CRISPR’s shortcomings.

EuroBiotech Report—EMA-Brexit, Cell Medica CEO, ReViral, RedHill and Astex

In this week's EuroBiotech Report, EMA sounds the alarm about its Brexit move; Cell Medica hires a CEO from Kite Pharma; ReViral raises $55 million and more. 

FiercePharmaAsia—Takeda earnings, GSK’s Bangladesh plant, Novartis-Laekna deal

Takeda's lack of late-stage assets underscores the importance of the Shire buyout; GlaxoSmithKline is closing a Bangladesh plant as part of its emerging markets revamp; Novartis licenses out two GSK-developed cancer drugs to Shanghai-based Laekna; and more.

Chutes & Ladders—Cell Medica names Kite’s European chief as CEO

CAR-T maker Cell Medica has named Kite’s European chief as CEO; Oncorus poached a Moderna cancer executive; and Achaogen has axed R&D and its C-suite. Those moves plus more hirings, firings and retirings throughout the industry.

Resources

[Whitepaper] Avoid Enrollment Pitfalls: Find Your Best-fit Clinical Trial Sites

Selecting the right sites is the most crucial decision you’ll make in your next clinical trial, and the single most important factor to consider in selecting a site is whether or not it can meet its enrollment goals.

[Survey] Industry Report: Findings from the 2018 Unified Clinical Operations Survey

Industry Research: See new results from one of the industry's largest, global clinical operations surveys.

[Whitepaper] How early planning and a unified data platform can cut trial timelines and cost.

Accelerate Clinical Research as Study Complexity Grows

[Whitepaper] Building the Business Case for RIM Transformation

Ready to modernize your RIM environment? Secure buy-in with these tips.

[Whitepaper] Rise in Targeted Therapies Drives Needs for Small Volume Manufacturing

Biologics, orphan drugs, and precision medicine are on the rise, and that means some big changes for drug development and manufacturing companies. What should pharma companies look for when navigating this new era of small-volume manufacturing? Here are some ideas to consider when developing a new manufacturing strategy.

[Whitepaper] eClinical Landscape Study - CRO Report from Tufts Center for the Study of Drug Development

See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs).

Events

.